We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
That was fast. Within a week of a surprise trial failure for Eli Lilly’s soft tissue sarcoma drug Lartruvo, regulators on both sides of the Atlantic have warned doctors not to start new patients on the drug.